Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

37 clinical studies listed.

Filters:

Weight Management

Tundra lists 37 Weight Management clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ENROLLING BY INVITATION

NCT07559409

CORE Study - Research Into Weight Management Services in the UK

Weight management services (previously known as Tier 3 services) represent a multidisciplinary specialist approach, available in community or secondary care settings. This tier caters to individuals with a Body Mass Index (BMI) greater than 35 (or over 30 if they have diabetes) and complex medical conditions, offering pharmacotherapy, low-energy liquid diets, and pre- and post-bariatric surgery care. Tier 4 services, located within secondary care, focus on bariatric surgery. Data on obesity rates are systematically collected by the National Audit Office, enabling monitoring of Tier 1 effectiveness. Additionally, the National Bariatric Database provides insights into bariatric surgery rates, patient characteristics, and surgical outcomes. However, comprehensive data on weight management services remain scarce, with information primarily available from only 4 of the 42 weight management clinics. Consequently, it is challenging to ascertain the availability of weight management services across different regions, the volume of referrals, the demographics of individuals accessing these services, and their outcomes during treatment. This lack of data hinders our ability to evaluate equitable access, appropriate referrals, and the overall effectiveness of these services throughout the UK.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-19

Weight Management
NOT YET RECRUITING

NCT07946471

A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Body Composition, Weight Management, Skin, Hair, Nail, Gut, and Overall Health Outcomes

This is a single-group, open-label, decentralized clinical trial evaluating the effects of 6 weeks of daily Glow Shakes Premium Collagen Meal Replacement consumption on body composition, weight management, and self-reported health outcomes in 40 adults aged 18-55 years with a BMI between 25-35 kg/m². All participants will consume Glow Shakes Premium Collagen Meal Replacement twice daily, replacing two typical meals, for 6 consecutive weeks. Assessments will be conducted at Baseline, Week 2, Week 4, and Week 6 and will include validated self-report questionnaires and body composition measurements via the Withings smart scale. All study activities are conducted remotely; products are shipped directly to participants' homes and all data are submitted digitally through the Citruslabs study platform.

Gender: All

Ages: 18 Years - 55 Years

Updated: 2026-11-18

1 state

Weight Management
Body Composition
Overweight
+4
NOT YET RECRUITING

NCT07946536

A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Nutritional Adequacy, Body Composition, Skin Health, Satiety, and Overall Wellness in Adults Using GLP-1 or Dual-Incretin Medications for Weight Management

This is a single-group, open-label, decentralized clinical trial evaluating the effects of 12 weeks of once-daily consumption of Glow Shakes Premium Collagen Meal Replacement on nutritional adequacy, body composition, skin health, satiety, and overall wellness in 40 adults aged 18-55 years who are currently using a GLP-1 receptor agonist or dual-incretin medication for weight management. All study activities are conducted remotely; participants complete questionnaire assessments and smart scale body composition measurements at home at Baseline, Week 4, Week 8, and Week 12. Participants replace a typical meal once daily with the study product for 12 consecutive weeks while continuing their existing GLP-1 or dual-incretin medication. The primary objective is to evaluate within-participant change in perceived nutritional adequacy from Baseline to Week 12. Secondary objectives include changes in body fat percentage, muscle mass, perceived skin health, hunger and satiety, hair health, energy and cognitive focus, nail health, gut comfort, metabolism support, physical strength, and product tolerability and satisfaction.

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-11-18

1 state

Weight Management
Obesity
Nutritional Adequacy
+4
RECRUITING

NCT07243171

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-11-16

1 state

Overweight and/or Obesity
Weight Management
NOT YET RECRUITING

NCT07936058

A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet

The aim of the study is to evaluate food effect on pharmacokinetics of oral ecnoglutide tablets in Chinese participants

Gender: All

Ages: 18 Years - 50 Years

Updated: 2026-11-13

1 state

Food Effect in Healthy Volunteers
Weight Management
NOT YET RECRUITING

NCT07936708

SA030 Injection in Healthy Participants

This is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses of SA030 injection in healthy participants. The planned dose levels include 100 mg, 200 mg, and 400 mg, with 8 eligible participants enrolled in each dose group. All participants receive a single administration of the study drug on Day 1 (D1). In each dose group, the first 2 participants are enrolled as sentinel participants and randomized at a 1:1 ratio to receive either SA030 injection or placebo. After a 5-day safety observation period and favorable safety assessment by the investigator, the remaining 6 participants in the group will be enrolled and randomized at a 5:1 ratio to receive SA030 injection or placebo. For dose escalation, at least 6 out of 8 participants in each dose group must complete the 14-day safety observation period (up to Day 15 \[D15\]). Subsequent dose escalation to the next higher dose level can only be initiated after safety review and approval by the Safety Review Committee (SRC).

Gender: All

Ages: 18 Years - 55 Years

Updated: 2026-11-13

1 state

Weight Management
RECRUITING

NCT07932977

Comprehensive Intervention for Changing Eating Habits Through Portion Control

This is a 12-month randomized controlled trial designed to evaluate the effectiveness of a comprehensive self-applied lifestlye intervention for weight loss, based on portion control. A total of 181 volunteers with overweight/obesity will be randomly allocated to an experimental intervention group or an active control group. The experimental intervention will include 4 components: (1) a portion control toolset (eating utensils); (2) a manual including instructions for the use of the tools, dietary and activity recommendations, and behavioural strategies; (3) a mobile app to motivate intervention engagement; and (4) a recipe book to help integrate the intervention in daily life. The control group will receive standard guidelines for healthy living, including diet and physical activity. Both groups will attend 4 clinical investigation days, 2 group sessions and will receive periodic telephone support. The primary outcome will be the change in waist circumference from baseline, assessed at 3, 9 and 12 months. Other measurements will include body composition, fasting biochemical parameters, eating behaviour, gut microbiota, functional magnetic resonance, portion size norms, intervention adherence and acceptance. The study will test the hypothesis that a comprehensive intervention focused on portion control can promote changes in eating habits and reduce waist circumference over 12 months compared with receving standard healthy living advice (active control group).

Gender: All

Ages: 18 Years - 70 Years

Updated: 2026-11-12

1 state

Lifestyle Intervention
Weight Management
Behaviour Change
+1
NOT YET RECRUITING

NCT07929298

A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

The aim of the study is to evaluate the safety and efficacy of oral ecnoglutide tablets in Chinese participants with overweight or obesity

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-11-10

1 state

Overweight , Obesity
Weight Management
ACTIVE NOT RECRUITING

NCT07895563

A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control

This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite, satiety, and energy levels in overweight and obese adults over six weeks. A total of 170 generally healthy adults aged 18-65 years with a BMI of 27.0-35.0 kg/m² will be randomized 1:1 to receive either the active supplement or a matching placebo. Participants will take three capsules orally twice daily for six weeks. All study activities are conducted remotely, including electronic consent, self-administered anthropometric measurements using a sponsor-provided Withings Scale and tape measure, and weekly online questionnaires via the Citruslabs digital study platform. The primary outcome is change in body weight from Baseline to Week 6.

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-10-26

1 state

Overweight
Obesity
Weight Management
+1
COMPLETED

NCT07889570

A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression

This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks. Participants are randomized to either the intervention group (8 capsules daily) or a control group receiving standardized healthy eating guidance from the American Diabetes Association. The study enrolls 98 male and female participants aged 18 and older with a BMI of 25-29.9 kg/m2. Primary endpoints include Hemoglobin A1c (HgbA1c) measured via bloodwork at Baseline, Week 6, and Week 12, as well as body weight and waist circumference measurements collected at Baseline, Week 4, Week 6, Week 8, and Week 12. Secondary endpoints capture participant perceptions of appetite suppression, weight loss, blood sugar, and overall well-being via self-reported questionnaires at the same time points.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-22

1 state

Overweight
Obesity
Blood Sugar Regulation
+2
RECRUITING

NCT07426952

Weight Management After Cancer for Survivors in Rural Communities

This study is testing a new program called WeCan-Rural, designed to help breast cancer survivors manage symptoms and build healthy habits like eating well, staying active, and managing their weight. These changes may help lower the risk of heart disease after cancer treatment. The study will answer two main questions: * Can study team successfully recruit and keep participants in the study, and will the participants find the program helpful and easy to follow? * Will participants who join the program see better results in areas like weight, symptoms, diet, physical activity, and confidence in managing the participant's health compared to those who receive standard care? Here's what participants will do: * Visit the participant's clinic twice (about 12 weeks apart) to be weighed, have the blood pressure checked, give a blood sample, and complete a short walking test * Fill out online surveys about the participant's health, diet, physical activity, symptoms, and confidence in managing the participant's health * Be randomly assigned (like flipping a coin) to either receive the WeCan-Rural program or standard health information * If assigned to the program, attend 12 weekly one-hour video sessions on Zoom with a trained therapist

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-10-16

1 state

Breast Cancer Survivorship
Weight Management
Cardiovascular (CV) Risk
+1
RECRUITING

NCT07667803

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-13

40 states

Weight Management
NOT YET RECRUITING

NCT07829016

GLP-1 Impacts on Weight Management

The goal of this observational study is to learn about the long-term effects of GLP-1RAs (Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound) in adolescents and young adults aged 12-21 who will start taking this drug for weight management. The main question it aims to answer is: How does starting GLP-1RAs impact eating behaviors and mental health symptoms? Participants starting to take GLP-1RAs as part of their medical care for weight management will answer online survey questions about their experience taking the drug for 1 year.

Gender: All

Ages: 12 Years - 21 Years

Updated: 2026-10-13

1 state

Weight Management
Disordered Eating Behaviors
RECRUITING

NCT06562907

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM). The primary objectives of this study are: * To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571. * To evaluate the effect of concomitant food intake and (if conducted) a representative acid-reducing agent (proton pump inhibitor (PPI), omeprazole) on the PK of GS-4571. * To evaluate the safety and tolerability of single and multiple ascending oral doses of GS-4571.

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-10-06

3 states

Weight Management
NOT YET RECRUITING

NCT07841860

A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose and in Obese Participants With Multiple Doses

This study is a randomized, double-blind, placebo-controlled, dose-escalation study that examines the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy participants and multiple administrations in obese participants.

Gender: All

Ages: 18 Years - 55 Years

Updated: 2026-09-25

1 state

Weight Management
Type 2 Diabetes
NOT YET RECRUITING

NCT07837999

Weight Management and Health Outcomes in College Students

The goal of this study is to learn if a weight management program can improve the overall health of college students. The main questions it aims to answer are: * Can a weight management program help college students improve their physical health, such as weight, blood pressure, and blood sugar? * Can the program also improve students' daily habits, like eating and exercise, and their emotional well-being? Researchers will compare students who take part in the weight management program with students who do not, to see if the program makes a difference. Participants in the program will: * Take part in regular sessions about healthy eating, physical activity, and weight management. * Receive support and guidance from trained staff. * Complete surveys and health checks before and after the program. This study is for college students who want to manage their weight and improve their health. Taking part may help students build healthier habits and feel better. The study will also help researchers understand how to design better health programs for college students in the future.

Gender: All

Ages: 18 Years - 26 Years

Updated: 2026-09-24

Weight Management
Health Outcomes
Cardiometabolic Health
RECRUITING

NCT06691100

How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types

This study aims to elucidate the differences in the gut microbiome functional activity and metabolome in adult premenopausal women with distinctive fitness levels and BMIs (with obesity, w/o obesity). The specific aims are as follows: * Aim 1: To examine the effects of acute aerobic exercise at 60-70% heart rate reserve (HRRmax) for 30 minutes bout on changes in the abundance of SCFA-producing bacteria and their functional downstream metabolic activity. * Aim 2: To examine the effects of acute aerobic exercise at 60-70% HRRmax 30-minute bout on changes in GM-released SCFA concentrations in stool and plasmatic metabolome.

Gender: FEMALE

Ages: 21 Years - 40 Years

Updated: 2026-09-09

1 state

Weight Management
Obesity
Exercise
+5
COMPLETED

NCT06519539

Implementing Strategies for Eating Behaviour Modification Based on Portion Control

This is a pre-post intervention study designed to evaluate the feasibility of a self-applied weight management intervention based on portion control. A total of 40 healthy volunteers with overweight/obesity will take part in a 6-month intervention featuring 4 components: a portion control toolset; a manual including instructions for the use of the tools, dietary and activity recommendations, and behavioural strategies; a mobile app to motivate intervention engagement; and biweekly telephone support. The primary outcome will be Intervention adherence, assessed as the change in dietary energy density, meal nutrient composition and utilization of intervention components from start to end of trial. Other measurements (at baseline, 3 and 6 months from baseline) will include body composition, fasting biochemical parameters, inhibitory control, eating behaviour, portions size norms and acceptance of the intervention.

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-09-01

1 state

Lifestyle, Healthy
Weight Management
Behavior Change
COMPLETED

NCT07765394

A Clinical Trial to Evaluate the Effects of A Supplement on Supporting Signs of Metabolic Health

This study evaluates the effects of the Love Wellness supplement Hello Burn Activate on supporting metabolic health in adult females. The 12-week, single-arm, open-label, virtual trial will enroll 40 female participants aged 25-45 who are experiencing challenges with healthy weight management and body confidence. All participants will take one capsule of the test product daily in the morning with their first meal. Participants will complete self-reported questionnaires at Baseline, Week 4, Week 8, and Week 12 to assess changes in perceived metabolic health, body confidence, overall health, and well-being.

Gender: All

Ages: 25 Years - 45 Years

Updated: 2026-08-14

1 state

Metabolic Health
Weight Management
Body Confidence
+1
RECRUITING

NCT05534386

A Self-management Based Survivorship Intervention for Chinese Cancer Survivors

This study, using a sequential multiple assessment randomized controlled trial (SMART) approach, will evaluate a cancer survivorship care intervention on physical symptom distress, weight management, self-efficacy in managing cancer and health-related quality of life among Chinese patients recently completed curative cancer treatment.

Gender: All

Ages: 18 Years - Any

Updated: 2026-08-13

Physical Symptom Distress
Weight Management
Neoplasms
ACTIVE NOT RECRUITING

NCT06877572

Weight Loss Management in Endometrial Cancer Survivors

This study is being done to understand how oncologists can engage a multidisciplinary team to help endometrial cancer survivors with obesity to engage in a weight management program and potentially start a weight loss medication. Obesity often impacts the future health and longevity of early-stage endometrial cancer survivors more than their cancer diagnosis. Patients will be referred to the KUMC OB/Gyn weight management clinic to discuss weight management options. * If patients decide to use medications for weight loss, then the study will collect data from their chart that is recorded as part of routine monitoring for patients on weight loss medications. * If patients decide not to use any medications, the study will monitor physical exam and lab data collected as part of their routine medical care. The study will also try to understand reasons why patients did or did not start using a weight loss medication.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-08-12

1 state

Endometrial Cancer Survivors
Weight Management
Early Stage Endometrial Cancer
RECRUITING

NCT07049861

Advancing Biopsychosocial Care Training Initiative

This project will compare two training approaches for US Preventive Services Task Force recommended obesity care in Federally Qualified Health Centers (FQHC) across four aims. Aim 1 compares patient-level effectiveness \[i.e., patient relative weight change and the proportion of patients who achieve clinically significant weight loss\]. Aim 2 compares reach (patient treatment utilization). Aim 3 compares primary care provider (PCP) referrals to USPSTF-recommended care at 12 (adoption) and 24 months (maintenance) and short- and long-term changes in provider obesity care competencies . Aim 4 compares implementation and service costs.

Gender: All

Ages: 5 Years - Any

Updated: 2026-08-10

1 state

Weight Management
Obesity Prevention
Obesity and Obesity-related Medical Conditions
+2
COMPLETED

NCT07089823

A Study of YP05002 in Healthy Participants

This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of YP05002 Tablets in healthy participants

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-07-30

1 state

Weight Management
RECRUITING

NCT06967389

Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity

The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: * How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment? * How do risk markers of disease change over the study in the study participants who are given semaglutides to help with weight loss? * Are there differences in the above factors between males and females and are there key factors to help improve the outcomes? Participants will be given semaglutide for this study. During the course of the study, participants will: * have two cardiac MRI scans OR two cardiac echocardiograms (one before starting semaglutide and one around 12 months after taking the drug) * have body composition and fitness levels assessed twice (before semaglutide and around 12 months after taking it) and have urine specific gravity (USG) measured * have extra blood drawn when labs their doctor orders are already being drawn (once at the beginning of the study, once around 6 months after enrollment, and once at the end of the study) * have follow up visits with the study doctor * be asked to take a pregnancy test if they are female and have started menstruation

Gender: All

Ages: 12 Years - 17 Years

Updated: 2026-07-21

1 state

Obesity and Overweight
Obese Adolescents
Weight Management
+2